Healthcare -
Biotechnology - NASDAQ - US
$ 0.582
-5.73 %
$ 1.49 M
Market Cap
-0.07
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
ZyVersa Therapeutics, Inc.
| Current Assets | 1.72 B |
| Cash & Short-Term Investments | 1.53 B |
| Receivables | 0 |
| Other Current Assets | 185 M |
| Non-Current Assets | 18.9 B |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 18.9 B |
| Current Liabilities | 11.2 M |
| Accounts Payable | 9.34 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 1.89 M |
| Non-Current Liabilities | 852 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 852 M |
EFFICIENCY
Earnings Waterfall
ZyVersa Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 9.14 B |
| Operating Income | -9.14 B |
| Other Expenses | 277 M |
| Net Income | -9.41 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ZyVersa Therapeutics, Inc.
| Net Income | -9.41 B |
| Depreciation & Amortization | 6.93 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 706 M |
| Change in Working Capital | 930 K |
| Others | 1.13 B |
| Free Cash Flow | -7.56 B |
Wall Street Analysts Price Targets
ZyVersa Therapeutics, Inc.
ZVSA has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ZVSA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
ZyVersa Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR 200's lead indication, focal segmental glomerulosclerosis (FSGS), expected to be shorter based on FDA's alignment with data supporting proteinuria reduction as a clinical trial endpoint for approval of FSGS drugs (Parasol Initiative).
globenewswire.com
- 3 weeks ago
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
Inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function in obesity-associated cardiomyopathy.
globenewswire.com
- 1 month ago
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model
WESTON, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights newly published data demonstrating that NLRP3 Inhibition attenuates development of AD pathology (buildup of Aβ) and neuroinflammation in a mouse model of AD, thereby attenuating disease progression.
globenewswire.com
- 1 month ago
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
WESTON, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, today announced that it has entered into a securities purchase agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 2,105,265 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,105,265 shares of common stock at an effective combined price of $0.95 per share and common warrant for aggregate gross proceeds of approximately $2.0 million, before deducting placement agent fees and other offering expenses.
globenewswire.com
- 1 month ago
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
Heart failure with preserved ejection fraction (HFpEF), a chronic inflammatory condition, is a leading cause of morbidity and mortality globally. Obesity, diabetes, and hypertension are highly prevalent in this population and usually precede HFpEF development.
globenewswire.com
- 1 month ago
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco
ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.
globenewswire.com
- 4 months ago
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
globenewswire.com
- 5 months ago
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025. New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications.
globenewswire.com
- 5 months ago
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells. Preserving pancreatic islet beta cell function is key to prevention of insulin resistance and development of type 2 diabetes.
globenewswire.com
- 5 months ago
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous immune-mediated disorders. With weight loss, less inflammation is expected, but adipose tissue inflammation can persist long after weight loss.
globenewswire.com
- 5 months ago
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer's and Parkinson's diseases The newly published data show that obesity leads to progressive brain inflammation in a mouse model, and that the proinflammatory processes worsen with prolonged obesity and with increased age This research supports our selection of obesity with associated comorbidities as the lead indication for Inflammasome ASC Inhibitor IC 100 IC 100 inhibits intra- and extracellular ASC and specks associated with multiple types of inflammasomes to attenuate damaging neurologic and systemic inflammation WESTON, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data published in the peer-reviewed journal, Aging Cell, demonstrating that obesity in older adults or prolonged duration of obesity in the younger population resulted in inflammation and suppression of neurotrophic/neuroprotective factors in the brain, indicating that age and duration of obesity are critical risk factors for neurodegenerative diseases.
globenewswire.com
- 5 months ago
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.
globenewswire.com
- 6 months ago
8. Profile
Summary
ZyVersa Therapeutics, Inc. ZVSA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.49 M
Dividend Yield
0.00%
Description
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Contact
2200 N. Commerce Parkway, Weston, FL, 33326
https://www.zyversa.com
IPO
Date
Feb. 11, 2022
Employees
7
Officers
Mr. Stephen C. Glover
Co-Founder, Chairman, Chief Executive Officer & President
Ms. Melda Uzbil O'connell
Senior Vice President of Corporate Development
Dr. Pablo A. Guzman FACC, M.D.
Chief Medical Officer, Senior Vice President of Medical Affairs & Chairman of Renal Scientific Advisory Board
Mr. Peter Wolfe
Chief Financial Officer & Secretary
Ms. Karen A. Cashmere
Chief Commercial Officer